Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Eleonora Trotta"'
Autor:
Marek Kovar, Vijay S. Pande, Jamie B. Spangler, Christina S. Savvides, Stephanie L. Silveria, K. Christopher Garcia, Ariana Peck, Joshua Salafsky, Eleonora Trotta, Jakub Tomala, Jeffrey A. Bluestone, Tracy A. Young, Petra Votavova
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950), vol 201, iss 7
Spangler, JB; Trotta, E; Tomala, J; Peck, A; Young, TA; Savvides, CS; et al.(2018). Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. JOURNAL OF IMMUNOLOGY, 201(7), 2094-2106. doi: 10.4049/jimmunol.1800578. UCSF: Retrieved from: http://www.escholarship.org/uc/item/30160235
Spangler, JB; Trotta, E; Tomala, J; Peck, A; Young, TA; Savvides, CS; et al.(2018). Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. JOURNAL OF IMMUNOLOGY, 201(7), 2094-2106. doi: 10.4049/jimmunol.1800578. UCSF: Retrieved from: http://www.escholarship.org/uc/item/30160235
IL-2 has been used to treat diseases ranging from cancer to autoimmune disorders, but its concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 orchestrates immune cell function through activation of a high-affinity heterot
Autor:
Marc Potempa, Eleonora Trotta, Isaac Rondon, Kevin Jude, Crellin Natasha Kay, Holst Charles Ray, Duy T. Le, Lewis L. Lanier, Anthony J. Coyle, Lauren Kate Ely, Stephanie L. Silveria, Paul Bessette, Jeffrey A. Bluestone, K. Christopher Garcia
Publikováno v:
Trotta, E; Bessette, PH; Silveria, SL; Ely, LK; Jude, KM; Le, DT; et al.(2018). A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. NATURE MEDICINE, 24(7), 1005-+. doi: 10.1038/s41591-018-0070-2. UCSF: Retrieved from: http://www.escholarship.org/uc/item/1dn2c0jw
Nature medicine, vol 24, iss 7
Nature medicine, vol 24, iss 7
Interleukin-2 (IL-2) has been shown to suppress immune pathologies by preferentially expanding regulatory T cells (T(regs)). However, this therapy has been limited by off-target complications due to pathogenic cell expansion. Recent efforts have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd427a1fdbb7cb36515a5c50a0f555dc
http://www.escholarship.org/uc/item/1dn2c0jw
http://www.escholarship.org/uc/item/1dn2c0jw
Publikováno v:
Science immunology. 3(25)
Interleukin-2 (IL-2), the first cytokine that was molecularly cloned, was shown to be a T cell growth factor essential for the proliferation of T cells and the generation of effector and memory cells. On the basis of this activity, the earliest thera
Autor:
Indigo Chris King, Akanksha Chhabra, David Baker, Leah V. Sibener, Matthew Tiffany, Antoni Ribas, Alan C. Le, Jeffrey A. Bluestone, Leon Su, Stephanie L. Silveria, Benson M. George, Eleonora Trotta, Jonathan T. Sockolosky, Giulia Parisi, Kevin Jude, Judith A. Shizuru, K. Christopher Garcia, Lora Picton
Publikováno v:
Science (New York, N.Y.), vol 359, iss 6379
Sockolosky, JT; Trotta, E; Parisi, G; Picton, L; Su, LL; Le, AC; et al.(2018). Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. SCIENCE, 359(6379), 1037-+. doi: 10.1126/science.aar3246. UCLA: Retrieved from: http://www.escholarship.org/uc/item/1fn5n8p9
Sockolosky, JT; Trotta, E; Parisi, G; Picton, L; Su, LL; Le, AC; et al.(2018). Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes. SCIENCE, 359(6379), 1037-+. doi: 10.1126/science.aar3246. UCLA: Retrieved from: http://www.escholarship.org/uc/item/1fn5n8p9
Engineering cytokine-receptor pairs Interleukin-2 (IL-2) is an important cytokine that helps T cells destroy tumors and virus-infected cells. IL-2 has great therapeutic promise but is limited by toxic side effects and its capacity to both activate an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89f7612e9b2dc674d79cf5a181507638
https://escholarship.org/uc/item/1fn5n8p9
https://escholarship.org/uc/item/1fn5n8p9
Autor:
Eleonora Trotta, Paul H. Bessette, Stephanie L. Silveria, Lauren K. Ely, Kevin Jude, Charles R. Holst, Anthony Coyle, Christopher K. Garcia, Natasha K. Crellin, Isaac J. Rondon, Jeffrey A. Bluestone
Publikováno v:
The Journal of Immunology. 200:176.4-176.4
Interleukin-2 (IL-2) has been shown to suppress immune pathologies by preferentially expanding regulatory T cells (Treg). However, this therapy has been limited by off-target complications due to pathogenic cell expansion. Recent efforts have been fo
Publikováno v:
Expert opinion on therapeutic targets, vol 19, iss 8
Bluestone, JA; Trotta, E; & Xu, D. (2015). The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opinion on Therapeutic Targets, 19(8), 1091-1103. doi: 10.1517/14728222.2015.1037282. UCSF: Retrieved from: http://www.escholarship.org/uc/item/6c73b1zw
Bluestone, JA; Trotta, E; & Xu, D. (2015). The therapeutic potential of regulatory T cells for the treatment of autoimmune disease. Expert Opinion on Therapeutic Targets, 19(8), 1091-1103. doi: 10.1517/14728222.2015.1037282. UCSF: Retrieved from: http://www.escholarship.org/uc/item/6c73b1zw
© 2015 Informa UK, Ltd. Immune tolerance remains the holy grail of therapeutic immunology in the fields of organ and tissue transplant rejection, autoimmune diseases, and allergy and asthma. We have learned that FoxP3+CD4+regulatory T cells play a v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d1718b55e319adcf5ff44eb4941859c
https://escholarship.org/uc/item/6c73b1zw
https://escholarship.org/uc/item/6c73b1zw